In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells

Autor: Jing-Bo Wu, Yu-Juan Zhou, Fang Xie, Zong-Jun-Lin Liu, Rui-Lin Ding, Qing-Lian Wen, Ling-Lin Yang, Shao-Zhi Fu
Rok vydání: 2018
Předmět:
Melanomas
0301 basic medicine
Skin Neoplasms
Pyridines
Physiology
Angiogenesis
Cell Culture Techniques
Cancer Treatment
lcsh:Medicine
Cardiovascular Physiology
Mice
Phosphatidylinositol 3-Kinases
chemistry.chemical_compound
0302 clinical medicine
Cell Movement
Medicine and Health Sciences
Enzyme assays
Electron Microscopy
Apatinib
Colorimetric assays
Extracellular Signal-Regulated MAP Kinases
lcsh:Science
Melanoma
Bioassays and physiological analysis
Cultured Tumor Cells
Staining
Mice
Inbred BALB C

Microscopy
MTT assay
Multidisciplinary
Neovascularization
Pathologic

Chemistry
Phase Contrast Microscopy
Cell Staining
Oncology
Cell Processes
030220 oncology & carcinogenesis
Matrix Metalloproteinase 2
Melanoma Cells
Female
Biological Cultures
Signal Transduction
Research Article
Cell Survival
Antineoplastic Agents
03 medical and health sciences
Gentamicin protection assay
In vivo
Cell Line
Tumor

Animals
Humans
Neoplasm Invasiveness
Vasculogenic mimicry
Viability assay
Cell Proliferation
Matrigel
Binding Sites
Cell growth
lcsh:R
Cancers and Neoplasms
Biology and Life Sciences
Cell Biology
Cell Cultures
Vascular Endothelial Growth Factor Receptor-2
Research and analysis methods
030104 developmental biology
Specimen Preparation and Treatment
Biochemical analysis
Cancer research
lcsh:Q
Drug Screening Assays
Antitumor

Neoplasm Transplantation
Developmental Biology
Zdroj: PLoS ONE, Vol 13, Iss 7, p e0200845 (2018)
PLoS ONE
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0200845
Popis: The effect of apatinib on the formation of vasculogenic mimicry (VM) was studied in a malignant melanoma cell line. MUM-2B cells cultured in three-dimensional Matrigel were treated with varying concentrations (0, 0.01, 0.05, 0.1, 0.5 μmol/L) of apatinib to test its effect on VM in vitro, followed by MTT proliferation and transwell invasion assays to determine the effect of apatinib on cell proliferation and invasion of MUM-2B cells. In vivo, we used a melanoma cancer model to test the effect of short-term apatinib (100, 200, 300 mg/kg) treatment on VM. Western blotting, immunohistochemistry staining, and CD31-PAS dual staining were performed to assess the expression of VEGFR-2, ERK-1/2, PI3K, and MMP-2, and formation of VM. The results showed apatinib-treated groups formed a lesser number of VM in 3D matrigel, while the cell viability in MTT proliferation assay and the number of migration cells in transwell invasion assay were significantly lower in apatinib-treated groups. In addition, short-term apatinib treatment inhibited angiogenesis, VM formation, and tumor growth in models of melanoma cancer. Mice in apatinib-treated groups showed a markedly reduced expression of VEGFR-2, ERK-1/2, PI3K, and MMP-2. In summary, apatinib could inhibit the expression of VEGFR-2, and downregulate the ERK1/2/PI3K/MMP-2 signaling cascade, which may be one of the underlying mechanisms by which apatinib inhibits angiogenesis and the development of VM in models of melanoma cancer, and restrains the formation of VM by MUM-2B cells. Apatinib shows inhibitory effects on cell proliferation and invasion of MUM-2B cells, which is a close relationship with the VM.
Databáze: OpenAIRE